I'm considering investing in CGS after researching the company and I like what I see but I'm just unsure about one thing.
Can any investors with a deeper knowledge of the business comment on whether the ability to detect Alzheimers using a blood test have a detrimental effect on CGS's operations?
Could this mean less assessments using CGS tests?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.005(0.28%) |
Mkt cap ! $305.5M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.82 | $1.78 | $95.65K | 53.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4401 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 3450 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |